Pat R. Brady
Directeur/Membre du Conseil chez Twinstrand Therapeutics, Inc.
Profil
Pat R.
Brady is currently a Director at Twinstrand Therapeutics, Inc. and Valocor Therapeutics, Inc. He has previously worked as a Director at Inimex Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc., MSI Methylation Sciences, Inc., Neurostream Technologies, Inc., Neuromed Pharmaceuticals Ltd., Protiva Biotherapeutics, Inc., and Celator Pharmaceuticals Corp.
He was also a Principal at DynaMotive Energy Systems Corp.
and Vice President of Investments at GrowthWorks Capital Ltd.
Mr. Brady holds an MBA degree from the University of Western Ontario.
Postes actifs de Pat R. Brady
| Sociétés | Poste | Début |
|---|---|---|
Twinstrand Therapeutics, Inc.
 Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | Directeur/Membre du Conseil | - |
Valocor Therapeutics, Inc.
 Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | Directeur/Membre du Conseil | 26/05/2010 |
Anciens postes connus de Pat R. Brady
| Sociétés | Poste | Fin |
|---|---|---|
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Directeur/Membre du Conseil | 23/11/2009 |
Protiva Biotherapeutics, Inc.
 Protiva Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA. | Directeur/Membre du Conseil | 02/12/2008 |
DynaMotive Energy Systems Corp.
 DynaMotive Energy Systems Corp. Chemicals: SpecialtyProcess Industries Dynamotive Energy Systems Corp. provides energy solutions. Its carbon and greenhouse gas neutral fast pyrolysis technology uses medium temperatures and oxygen-less conditions to turn dry, waste cellulosic biomass into BioOil and Bio Char. The firm develops an upgrading process to produce transport fuels from pyrolysis oils. The company was founded in 1990 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
MSI Methylation Sciences, Inc.
 MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Directeur/Membre du Conseil | - |
Celator Pharmaceuticals Corp.
 Celator Pharmaceuticals Corp. BiotechnologyHealth Technology Celator Pharmaceuticals Corp. is an oncology-based biopharmaceutical company. It focuses on a proprietary technology platform which evaluates combinations of anti-cancer drugs for enhanced anti-cancer activity. The company was founded by Lawrence David Mayer and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | - |
Formation de Pat R. Brady
| University of Western Ontario | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
DynaMotive Energy Systems Corp.
DynaMotive Energy Systems Corp. Chemicals: SpecialtyProcess Industries Dynamotive Energy Systems Corp. provides energy solutions. Its carbon and greenhouse gas neutral fast pyrolysis technology uses medium temperatures and oxygen-less conditions to turn dry, waste cellulosic biomass into BioOil and Bio Char. The firm develops an upgrading process to produce transport fuels from pyrolysis oils. The company was founded in 1990 and is headquartered in Vancouver, Canada. | Process Industries |
Inimex Pharmaceuticals, Inc.
 Inimex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inimex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of Innate Defense Regulators (IDRs). IDRs are novel drugs that selectively trigger the body's innate defenses, protecting against antibiotic-resistant infections and controlling inflammation. The company was founded in 2001 and is headquartered in Vancouver, Canada. | Health Technology |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ. | Health Technology |
MSI Methylation Sciences, Inc.
MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Health Technology |
GrowthWorks Capital Ltd.
 GrowthWorks Capital Ltd. Investment ManagersFinance GrowthWorks Capital Ltd. (GrowthWorks) is a venture capital firm founded in 1992 by David Levi. The firm is headquartered in Vancouver, Columbia with additionaal offices in Saskatchewan, Manitoba, New Brunswick, Newfoundland, Nova Scotia, and Ontario. | Finance |
Neurostream Technologies, Inc.
 Neurostream Technologies, Inc. Medical SpecialtiesHealth Technology Neurostream Technologies focuses on the development and commercialization of technologies and products that address unmet medical needs of patients suffering from neurological, neuromuscular or movement disorders. Neurostream Technologies is part of the Otto Bock Group, a global leader in orthotics-prosthetics. | Health Technology |
Neuromed Pharmaceuticals Ltd.
 Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
Protiva Biotherapeutics, Inc.
Protiva Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA. | Health Technology |
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | Health Technology |
Celator Pharmaceuticals Corp.
Celator Pharmaceuticals Corp. BiotechnologyHealth Technology Celator Pharmaceuticals Corp. is an oncology-based biopharmaceutical company. It focuses on a proprietary technology platform which evaluates combinations of anti-cancer drugs for enhanced anti-cancer activity. The company was founded by Lawrence David Mayer and is headquartered in Vancouver, Canada. | Health Technology |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
Valocor Therapeutics, Inc.
Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | Health Technology |
